Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an 'estrogen independent' breast tumor

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 981-986

  England, Gale M ^a   Bilimoria, Malcolm M ^a   Chen, Zehan ^a   Assikis, Vasilios J ^a   Muenzner, Henry D ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Estrogen receptor; Genetic mutation

Indexed keywords

ANIMAL CELL; ARTICLE; BINDING SITE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; DNA SEQUENCE; FEMALE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; MOUSE; NONHUMAN; NUDE MOUSE; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR DENSITY; SEQUENCE ANALYSIS;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL DIVISION; DNA PRIMERS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GLYCINE; HUMANS; LUCIFERASES; MICE; MICE, NUDE; OVARIECTOMY; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VALINE;

EID: 0031955339     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Walter P, Green S, Greene G, Krust A, Bomert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, et al: Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82: 7889-7893, 1985.
2. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y and Shine J: Sequence and expression of human estrogen receptor cDNA. Science 231: 1150-1154, 1986.
3. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
4. Kumar V and Chambon P: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55: 145-156, 1988.
5. Katzenellenbogen BS, Miller MA, Mullick A and Sheen YY: Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis and interaction with estrogen receptors and additional anti-estrogen binding sites. Breast Cancer Res Treat 5: 231-243, 1985.
6. Beato M: Gene regulation by steroid hormones. Cell 56: 335-344, 1989.
7. Kumar V, Green S, Stack G, Berry M, Jin J-R and Chambon P: Functional domains of the human estrogen receptor. Cell 51: 941-951, 1987.
8. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E and Chambon P: The human estrogen receptor has two independent non-acidic transcriptional activation functions. Cell 59: 477-487, 1989.
9. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE and Evans RM: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237: 268-275, 1987.
10. Hard T, Kellenbach E, Boelens R, Maler BA, Dahlman K, Freedman LP, Carlstedt-Duke J, Yamamoto KR, Gustafsson JA and Kaptein R: Solution structure of the glucocorticoid receptor DNA-binding domain. Science 249: 157-160, 1990.
11. Lees JA, Fawell SE and Parker MG: Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res 17: 5477-5488, 1989.
12. Wrenn CK and Katzenellenbogen BS: Structure-function analysis of the hormone binding domain of the human estrogen receptor by region specific mutagenesis and phenotypic screening in yeast. J Biol Chem 268: 24089-24098, 1993.
13. Harlow KW, Smith DN, Katzenellenbogen JA, Greene GL and Katzenellenbogen BS: Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J Biol Chem 264: 17476-17485, 1989.
14. Fawell SE, Lees JA, White R and Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse oestrogen receptor. Cell 60: 953-962, 1990.
15. Ekena K, Weis KE, Katzenellenbogen JA and Katzenellenbogen BS: Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem 271: 20053-20059, 1996.
16. Pakdel F and Katzenellenbogen BS: Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 267: 3429-3437, 1992.
17. Danielian PS, White R, Hoare SA, Fawell SE and Parker MG: Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7: 232-240, 1993.
18. Catherino WH, Wolf DM and Jordan VC: A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 9: 1053-1063, 1995.
19. Mahfoudi A, Roulet E, Dauvois S, Parker MG and Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92: 4206-4210, 1995.
20. Montano MM, Ekena K, Krueger KD, Keller AL and Katzenellenbogen BS: Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10: 230-242, 1996.
21. Zhang Q-X, Borg Å, Wolf DM, Oesterreich S and Fuqua SAW: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 57: 1244-1249, 1997.
22. Assikis VJ, Bilimoria MM, Muenzner HD, Lurain JR and Jordan VC: Mutations of the estrogen receptor in endometrial carcinoma: evidence of an association with high tumor grade. Gynecol Oncol 63: 192-199, 1996.
23. Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME and Jordan VC: Reversible control of oestradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse. Br J Cancer 64: 1019-1024, 1991.
24. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
25. Wolf DM and Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31: 129-138, 1994.
26. Catherino WH and Jordan VC: Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92: 39-47, 1995.
27. McGuire WL and Clark GM: The prognostic role of progesterone receptors in human breast cancer. Semin Oncol 10: 2-6, 1983.
28. DeSombre ER, King WJ, Greene GL, Thorpe SM, Rose C and Jensen EV: Estrogen receptor studies. Laboratory investigations and clinical applications. In: Estrogen/Antiestrogen Action and Breast Cancer Therapy. Jordan VC (ed.) University of Wisconsin Press, Wisconsin, pp303-323, 1986.
29. Olea N, Sakabe K, Soto AM and Sonnenschein C: The proliferative effect of 'anti-androgens' on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126: 1457-1463, 1990.
30. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Classen C, van Rooij HCJ, Trapman J, Brinkman AO and Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects the steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540, 1990.
31. Hughes MR, Malloy PJ, O'Malley BW, Pike JW and Feldman D: Genetic defects of the 1,25-dihydroxyvitamin D3 receptor. J Recept Res 11: 699-716, 1991.
32. Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P and Gronemeyer H: Switching agonistic, antagonistic and mixed transcriptional responses to 11-beta-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 6: 2071-2078, 1992.
33. Sultan C, Lumbroso S, Poujol N, Belon C, Boudon C and Lobaccaro JM: Mutations of androgen receptor gene in androgen insensitivity syndromes. J Steroid Biochem Mol Biol 45: 519-530, 1993.
34. Jiang S-Y and Jordan VC: Growth regulation of estrogen-receptor negative cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591, 1992.
35. Jiang S-Y, Langan-Fahey SM, Stella AL, McCague R and Jordan VC: Point mutation of estrogen receptor (ER) in the ligand binding domain changes the pharmacology of anti-estrogens in ER-negative breast cancer cells stably expressing cDNA's for ER. Mol Endocrinol 6: 2167-2174, 1992.
36. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW and McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105-109, 1991.
37. Zhang Q-X, Borg A and Fuqua SAW: An exon 5 deletion variant of the estrogen receptor frequently co-expressed with wild-type estrogen receptor in human breast cancer. Cancer Res 53: 5882-5884, 1993.
38. Danielian PS, White R, Lees JA and Parker MG: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11: 1025-1033, 1992.
39. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Ōhman L, Greene GL, Gustafsson J-Å and Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997.
40. Katzenellenbogen BS, Kendra KL, Norman MJ and Berthois Y: Proliferation, hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47: 4355-4360, 1987.
41. Welshons WV and Jordan VC: Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23: 1935-1939, 1987.